Stay Connected

btn-sc-social-community btn-sc-social-facebook btn-sc-social-twitter btn-sc-social-youtube btn-sc-social-newsletters



Get the practical information you need to live better with arthritis delivered straight to your inbox!

Arthritis Today

How to reduce pain, find the right treatments and live better with arthritis. [Bi-weekly]

Fitness + Nutrition

Get weight-loss tips, arthritis-friendly recipes and ways to exercise safely. [Bi-weekly]

Mind, Body, Spirit

Find arthritis care tips, inspirational stories and Arthritis Foundation news. [Monthly]

Research Update

Discover advancements made by Arthritis Foundation-funded researchers. [Quarterly]

OA Insider

Beyond the basics of osteoarthritis: research, news and treatment. [Monthly]

RA Insider

Beyond the basics of rheumatoid arthritis: research, news and treatment. [Monthly]

sign up



Drug Class:


Brand Names




For adults with active psoriatic arthritis: Starting dose 10 mg daily increased over five days to a maintenance dose of 30 mg twice a day. A lower dosage of 30 mg once a day is recommended for patients with severe kidney disease.

Potential Side Effects


Diarrhea; headache; nausea; weight loss.

Be Aware

  • Do not take with strong cytochrome P450 enzyme inducers such as carbamazepine, rifampin, phenobarbital or phenytoin.

    You should monitor your weight regularly when taking this drug. Tell your doctor if you have unexplained or clinically significant weight loss occurs.

    This drug may cause depression or worsening of depression. Tell your doctor if you have new or worsening depression, suicidal thoughts or other mood changes.

The Arthritis Today Drug Guide is meant for education – not self-medicating. Arthritis Today, the Arthritis Foundation and the Drug Guide Medical Review Panel do not endorse any products mentioned in this guide. While we endeavor to keep the information up to date, we make no representations or warranties about the completeness of the information provided.

About Arthritis Today Drug Guide | Privacy Policy | Medical Review Panel